A prospective multicentric study of microbiological profile, treatment protocols and clinical indicators of cure in skull base osteomyelitis
European Archives of Oto-Rhino-Laryngology · 2026
DOI: 10.1007/s00405-025-09613-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2026. Verfasst von Bini Faizal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeedham University, Kochi, India. binifaizal@gmail.com. Hauptthemen laut MEDLINE: Osteomyelitis, Anti-Bacterial Agents, Skull Base. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: To find the microbial profile, effective treatment protocols and indicators of cure in skull base osteomyelitis(SBO). METHODS: This prospective multicentric observational study involved 235 diagnosed SBO cases who satisfied the inclusion criteria from12 tertiary care centres. Minimum follow up(FU) was 6 months and maximum, 24 months. Osteomyelitis following trauma, radiotherapy and malignancy were excluded. Culture directed or empirical antipseudomonal intravenous antibiotics(IVAB) from a predetermined pool, were administered for 4 to 6 weeks, then switched to oral therapy for 4 weeks with improvement in pain, discharge, and or canal wall edema with declining inflammatory markers. Antifungals were administered when there was no response to IVABs and deep biopsy, not possible. Outcome measures were defined as cured, relieved, symptomatic or expired. RESULTS: Bacterial culture- Positive in 60.4% with Pseudomonas Aeruginosa (PA) (57.75%), Staphylococcus aureus (SA) (26.06%) and fungus (10.4%). MRSA was 62.2%. Pseudomonal sensitivity to Piperacillin, Ciprofloxacin, Ceftazidime, Levofloxacin and Cefoperazone was 67.1%, 56.10%, 54.90%, 40.20%, and 36.60% respectively and resistance was 11%, 31.7%, 14.6%, 20.7%, and 13.4%. Average total duration of AB was 8 weeks. At the end of the study, 43.4% were cured, 15.7% were relieved, 5.1% were symptomatic and 16.2% expired. A normal ESR and CRP at 3rd and 6th month, indicated cure (p- < 0.001). CONCLUSIONS: Microbial profile in our study was PA in 57.75% of positive cultures. The most effective treatment protocols were Piperacillin- Levofloxacin and Piperacillin. Normal inflammatory markers at the end of the 3rd and 6th month indicated a cure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeedham University, Kochi, India. binifaizal@gmail.com.
- Government Medical College, Kozhikode, 673008, India.
- Govt Medical College, Manjeri, India.
- Dr Manoj's ENT Hospital, 2/44 A East Hill Junction, West Hill PO, Calicut, 673005, India.
- Government T D Medical College, Alappuzha, India.
- Ascent ENT Hospital, Perinthalmanna, Malappuram, India.
Zitieren
APA
Faizal, B., K P, S. K., Radhakrishnan, S., M P, M., K P, S., P K, S., A T, I., Dominic, M., George, R. R., George, B. R., P, S., Thomas, I., & V S, S. (2026). A prospective multicentric study of microbiological profile, treatment protocols and clinical indicators of cure in skull base osteomyelitis. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-025-09613-4
Vancouver
Faizal B, K P SK, Radhakrishnan S, M P M, K P S, P K S, et al. A prospective multicentric study of microbiological profile, treatment protocols and clinical indicators of cure in skull base osteomyelitis. European Archives of Oto-Rhino-Laryngology. 2026. doi:10.1007/s00405-025-09613-4
BibTeX
@article{Faizal2026,
author = {Faizal, Bini and K P, Sunil Kumar and Radhakrishnan, Suma and M P, Manoj and K P, Shaira and P K, Sarafudeen and A T, Ihsan and Dominic, Mathew and George, Rajesh Raju and George, Binu Raju and P, Shajid and Thomas, Ike and V S, Sheejamol},
title = {A prospective multicentric study of microbiological profile, treatment protocols and clinical indicators of cure in skull base osteomyelitis},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2026},
doi = {10.1007/s00405-025-09613-4}
}
EUVIMED